---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-336886"
form_type: "8-K"
ticker: "CGON"
cik: "0001991792"
company_name: "CG Oncology, Inc."
filed_at: "2026-08-06T12:30:16+00:00"
generated_at: "2026-08-06T12:35:38.314821+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CG Oncology Q2 net loss $79.1M ($0.90/shr); adds $500M ATM capacity

## Summary
- Net loss of $79.1M ($0.90 per share) vs $41.4M ($0.54) in Q2 2025; R&D $54.7M, G&A $29.0M.
- Cash, equivalents and marketable securities $1.0B as of June 30, 2026, down from $1.1B on March 31, 2026.
- Filed Amendment No. 2 to Prospectus to increase ATM shares by $500M (previously sold ~$550M).
- PIVOT-006 Phase 3 topline data for cretostimogene in intermediate-risk NMIBC expected near-term.
- BLA submission for HR BCG-unresponsive NMIBC with CIS expected Q4 2026.

## SEC filing metadata
- accession: 0001193125-26-336886
- form_type: 8-K
- ticker: CGON
- cik: 0001991792
- company_name: CG Oncology, Inc.
- filed_at: 2026-08-06T12:30:16+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1991792/000119312526336886/0001193125-26-336886-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1991792/000119312526336886/ck0001991792-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-336886
- JSON: https://secwatch.observer/filing/0001193125-26-336886.json
- Plain text: https://secwatch.observer/filing/0001193125-26-336886.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.